Preoperative Atorvastatin Treatment in CABG Patients Rapidly Improves Vein Graft Redox State by Inhibition of Rac1 and NADPH-Oxidase Activity

Author:

Antoniades Charalambos1,Bakogiannis Constantinos1,Tousoulis Dimitris1,Reilly Svetlana1,Zhang Mei-Hua1,Paschalis Andreas1,Antonopoulos Alexios S.1,Demosthenous Michael1,Miliou Antigoni1,Psarros Costas1,Marinou Kyriakoula1,Sfyras Nikolaos1,Economopoulos George1,Casadei Barbara1,Channon Keith M.1,Stefanadis Christodoulos1

Affiliation:

1. From the Department of Cardiovascular Medicine (C.A., S.R., M.-H.Z., B.C., K.M.C.), University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; First Department of Cardiology (C.A., C.B., D.T., A.P., A.S.A., M.D., A.M., C.P., K.M., C.S.), University of Athens, Hippokration Hospital, Greece; and Department of Cardiac Surgery (A.P., N.S., G.E.), Hippokration Hospital, Athens, Greece.

Abstract

Background— Statins improve clinical outcome of patients with atherosclerosis, but their perioperative role in patients undergoing coronary artery bypass grafting (CABG) is unclear. We hypothesized that short-term treatment with atorvastatin before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-density lipoprotein cholesterol (LDL)-lowering. Methods and Results— In a randomized, double-blind controlled trial, 42 statin-naïve patients undergoing elective CABG received atorvastatin 40 mg/d or placebo for 3 days before surgery. Circulating inflammatory markers and malondialdehyde (MDA) were measured before and after treatment. SVG segments were used to determine vascular superoxide (O 2 ·− ) and Rac1 activation. For ex vivo studies, SVG segments from 24 patients were incubated for 6 hours with atorvastatin 0, 5, or 50 μmol/L. Oral atorvastatin reduced vascular basal and NADPH-stimulated O 2 ·− in SVGs ( P <0.05 for all versus placebo) and reduced plasma MDA ( P <0.05), independently of LDL-lowering and of changes in inflammatory markers. In SVGs exposed to atorvastatin ex vivo, without exposure to LDL, basal and NADPH-stimulated O 2 ·− were significantly reduced ( P <0.01 for both concentrations versus 0 μmol/L) in association with a striking reduction in Rac1 activation and 1 membrane-bound Rac1 and p67 phox subunit. The antioxidant effects of atorvastatin were reversed by mevalonate, implying a dependence on vascular HMG-CoA reductase inhibition. Conclusions— Short-term treatment with atorvastatin 40 mg/d before CABG improves redox state in SVGs, by inhibiting vascular Rac1-mediated activation of NADPH-oxidase. These novel findings suggest that statin therapy should be maintained or initiated in patients undergoing CABG, independently of LDL levels. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01013103.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3